Skip to main content

Table 5 Subgroup analysis for progression-free survival, overall survival and objective response rate

From: Gefitinib provides similar effectiveness and improved safety than erlotinib for east Asian populations with advanced non–small cell lung cancer: a meta-analysis

Group

PFS

OS

ORR

No.of studies

HR (95% CI)

P

I2 (%)

No.of studies

RR (95% CI)

P

I2 (%)

No.of studies

RR (95% CI)

P

I2 (%)

Total

24

1.04 (0.97–1.10)

0.26

38

21

1.04 (0.89–1.21)

0.61

58

13

1.08 (1.00–1.18)

0.06

20

Nation

 Keroa

8

0.89 (0.78–1.02)

0.09

18

8

1.03 (0.85–1.23)

0.79

0

5

1.18 (0.94–1.49)

0.16

0

 China

6

1.05 (0.88–1.25)

0.63

20

5

0.92 (0.62–1.36)

0.67

67

2

0.87 (0.70–1.08)

0.21

0

 Japan

6

1.15 (0.98–1.36)

0.09

20

4

1.04 (0.84–1.27)

0.74

0

3

1.18 (0.98–1.41)

0.08

0

 Taiwan

4

1.09 (0.77–1.54)

0.62

74

4

1.12 (0.75–1.67)

0.59

90

3

1.07 (0.86–1.35)

0.54

71

Tumor stage

 IIIb-IV

22

1.04 (0.98–1.10)

0.23

40

18

1.08 (0.92–1.26)

0.34

53

12

1.09 (1.00–1.18)

0.05

24

 I-IV

2

0.77 (0.39–1.51)

0.45

25

3

0.54 (0.18–1.63)

0.27

80

1

0.46 (0.05–4.01)

0.48

NA

History

 Non-squamous

13

1.04 (0.96–1.14)

0.88

51

11

1.06 (0.86–1.31)

0.58

68

9

1.08 (0.99–1.17)

0.09

42

 Squamous included

10

1.02 (0.94–1.12)

0.6

11

9

0.98(0.86–1.13)

0.81

48

4

1.19 (0.81–1.77)

0.38

0

 Unclear

1

3.05 (0.84–11.09)

0.09

NA

1

1.34 (0.49–3.67)

0.57

NA

    

Treatment line

 First line included

14

1.09 (0.98–1.20)

0.11

46

11

0.97 (0.72–1.30)

0.82

77

7

1.06 (0.90–1.25)

0.52

52

 Second line or later

8

1.01 (0.93–1.08)

0.89

22

8

1.02 (0.91–1.14)

0.78

0

6

1.15 (0.98–1.35)

0.08

0

 First line only

3

0.89 (0.32–2.49)

0.82

66

2

0.24 (0.04–1.43)

0.12

75

    

 Second line only

3

0.93 (0.76–1.14)

0.5

0

2

1.25 (0.90–1.73)

0.19

0

2

1.18 (0.76–1.82)

0.47

0

 Third line only

1

0.88 (0.43–1.79)

0.72

NA

2

0.96 (0.81–1.14)

0.47

0

1

0.46 (0.05–4.01)

0.48

NA

 Unclear

2

1.48 (0.72–3.08)

0.29

43

2

1.22 (0.62–2.39)

0.56

0

    

EGFR mutation

 Partial mutation

11

1.02 (0.91–1.15)

0.68

21

11

1.15 (0.91–1.45)

0.24

68

9

1.10 (1.00–1.21)

0.05

21

 All mutation

9

1.11 (0.90–1.36)

0.33

50

7

0.82 (0.54–1.25)

0.36

59

2

0.88 (0.71–1.09)

0.24

0

 Unclear

4

0.98 (0.76–1.26)

0.88

57

3

0.97 (0.84–1.13)

0.67

0

2

1.22 (0.92–1.62)

0.18

2

Study design

 Retrospective study

21

1.02 (0.95–1.09)

0.37

40

18

1.01 (0.84–1.21)

0.92

63

10

1.10 (1.00–1.22)

0.06

19

 RCT

3

1.11 (0.96–1.27)

0.15

32

3

1.11 (0.93–1.32)

0.25

0

3

1.04 (0.90–1.20)

0.62

36

  1. Abbreviations: PFS progression-free survival, OS overall survival, ORR objective response rate, ORR objective response rate, HR hazard ratio, RR relative risk, RCT randomized controlled trial, NA not available
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us